Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

motilin receptor found on smooth muscle cells of the GI tract and elements of the enteric nervous system. The clinical observation that the macrolide antibiotic erythromycin, a motilin receptor agonist, accelerates gastric emptying in patients with diabetic gastroparesis (impaired gastric emptying) has resulted in efforts to develop non-antibiotic macrolides (motilides) as prokinetic agents. PF-04548043 is a potent, selective motilin receptor agonist that is chemically stable and orally bioavailable and lacks antibiotic activity. In preclinical studies, PF-04548043 showed an improved safety profile relative to erythromycin and accelerated gastric emptying, suggesting that it may provide symptom relief in several GI diseases.

About GERD

Although the pathophysiology underlying GERD is not fully understood, it is clear that GERD is not due to acid hyper-secretion, but rather, is due to a combination of disordered upper GI tract motility, resulting in increased ingress of gastric contents into the lower esophagus, together with impairments in esophageal clearance and protection mechanisms. Increased exposure to gastric contents, coupled with reduced ability to clear the bolus, appears to precipitate reflux symptoms. Despite adequate control of intra-gastric acidity with proton pump inhibitors, a proportion of GERD patients continues to have residual symptoms. Through improvement of GI motility and increases in the rate of gastric emptying, PF-04548043 has the potential to reduce the exposure of the esophagus to acidic and weakly acidic reflux and this may improve the symptoms of GERD.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 in
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- In part four of a blog series ... a strategic asset, Mary Baxter, MBA, RPh ., ... Innovation Delivery Solutions business, discusses how expanding patient access ... patients. "Every hospital pharmacist knows that filling ... in a value-based healthcare world," Baxter says. "For the ...
(Date:8/29/2014)... ROBLES, Calif. , Aug. 29, 2014  Pacific ... of its new website design . The main ... overhaul that showcases the company,s new services and content ... By implementing a new streamlined design, viewers can now ... metrics for health care practices and create a more ...
(Date:8/29/2014)... 2014 Pixcelldata, the innovative Irish ... announced a major new deal with Dutch based eX-Path, ... expert, Dr. Marius Nap . The ... Congress of Pathology which is taking placing between August ... London where Pixcelldata will demonstrate its ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4PMDS Announces New Website 2Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
... -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... from its ZFP Therapeutic program to develop SB-509, a ... endothelial growth factor (VEGF)-A gene as a treatment for ... drug was well-tolerated in subjects with ALS and that ...
... 17, 2010 The Amgen Foundation and Ashoka,s Changemakers today ... Empowerment competition and launched public online voting in search ... voices, and improve health outcomes. The ten ... from 277 entries received from 40 countries. Online ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 2Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 3Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 4Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 5Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 6Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 7Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 2Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 3Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 4
(Date:8/30/2014)... OH (PRWEB) August 30, 2014 United Theological ... first fully online degree, the Master of Theological Studies (MTS). ... in 2-3 years, is designed for students who wish to ... their understanding and capacity to serve the Church and community. ... degree, but now they can attend classes from any location ...
(Date:8/30/2014)... Daily Gossip reveals in its review a ... You program, who shows a unique formula to get inside ... method says that the program goes beyond mere attraction and ... You review indicates that the program was created by dating ... great techniques to make a man feel emotionally addicted. , ...
(Date:8/30/2014)... The Plastic Surgery Group (PSG) is ... even in the U.S. to provide clients with Vanquish, ... patients’ waists with deep-tissue heating. , Unlike Cryotherapy which ... is more inclusive to target large sections of desired ... panels about one inch away from their body while ...
(Date:8/30/2014)... York, NY (PRWEB) August 30, 2014 ... authentic U.S. Open Tennis Championship tickets in ... customer appreciation promo/coupon code US-OPEN-2014 for all day session, ... seats and group sales for this prestigious Grand Slam ... is below: , 8/30/14 , US Open Tennis Championship: ...
(Date:8/30/2014)... August 30, 2014 Acne is a common problem ... acne is nothing more than a daily nuisance, for some, it ... cases of acne can even lead to dramatic mood swings and ... try anything to clear up their skin. In some cases, that ... money through trial and error, those on a quest for clearer ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Acne Treatment Reviews Added to Popular Treatment Website 2
... white paper that examines various state initiatives to expand access ... and Congress in support of state efforts, was distributed today ... The paper, State Experimentation with Reforms to Expand Access to ... part of any state-based reform. It is a summary of ...
... Ill., Sept. 14 The board of,directors of Abbott ... share. This marks the 335th consecutive quarterly dividend ... is payable Nov. 15, 2007, to,shareholders of record at ... About Abbott Abbott (NYSE: ABT ) is ...
... 14 As the political turmoil,surrounding stem cells rages ... and treatment - that saved his life. John E. ... -, http://www.authorhouse.com ), recounts the courageous five-year battle the,author ... cancer. Settling into a comfortable retirement with his ...
... of Texas Medical Branch at Galveston are trying to ... can also be used to delay delivery in expectant ... would give hope to hundreds of thousands of women ... drug, Digibind, has been prescribed for over 20 years ...
... Sept. 14 People,s United,Financial (Nasdaq: PBCT ) ... Klein, had undergone surgery to address a recurrence of,cancer ... surgery. He reported,in an e-mail to all employees that ... bank in early October. He stated that he is ...
... - Philly-Area Employers Get Moving by Putting on ... AstraZeneca continues,its fight against sedentary lifestyles by ... in Philadelphia to promote,walking and other healthy habits ... a Start! "walkforce" team to participate in,today,s Philadelphia ...
Cached Medicine News:Health News:Internal medicine physicians recommend key elements to guide state initiatives 2Health News:Internal medicine physicians recommend key elements to guide state initiatives 3Health News:The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival 2Health News:AstraZeneca Joins Local Walking Movement 2Health News:AstraZeneca Joins Local Walking Movement 3Health News:AstraZeneca Joins Local Walking Movement 4
... The BioPlex 2200 system is ... platform that can deliver up to ... will initially include a panel of ... in development are in the areas ...
... ASR contains primers and a FAM-labeled probe targeting ... as well as primers and an Alexa 532-labeled ... of HSV Type 2. This ASR requires an ... Alexa reporter dyes like the Cepheid SmartCycler System. ...
... and a FAM-labeled probe that is designed to ... Type 1 and Type 2 polymerase gene. This ... FAM reporter dye like the Cepheid SmartCycler System. ... is comprised of a series of easy-to-use primer ...
... The Stratus CS Analyzer, designed for Acute Care ... your laboratory and near patient setting. It's a ... or D-Dimer results from a whole blood sample ... 3 step process load sample and rotor, ...
Medicine Products: